Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Identifieur interne : 002E97 ( Ncbi/Merge ); précédent : 002E96; suivant : 002E98Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Auteurs : Peter Hillmen [Royaume-Uni] ; Petra Muus [Pays-Bas] ; Jeffrey Szer [Australie] ; Anita Hill [Royaume-Uni] ; Britta Höchsmann [Allemagne] ; Austin Kulasekararaj [Royaume-Uni] ; Antonio M. Risitano [Italie] ; Eric Van Den Neste [Belgique] ; Maria Liljeholm [Suède] ; Kurt S. Ebrahim [États-Unis] ; Camille L. Bedrosian [États-Unis] ; Xiang Gao [États-Unis] ; Donna Ames [États-Unis] ; Gérard Socié [France]Source :
- American journal of hematology [ 1096-8652 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Anticorps neutralisants (sang), Complément C5 (antagonistes et inhibiteurs), Facteurs temps, Femelle, Humains, Hémoglobinurie paroxystique (immunologie), Hémoglobinurie paroxystique (sang), Hémoglobinurie paroxystique (traitement médicamenteux), Hémolyse (), Hémolyse (immunologie), Inhibiteurs du complément (administration et posologie), Inhibiteurs du complément (effets indésirables), Inhibiteurs du complément (usage thérapeutique), Mâle, Relation dose-effet des médicaments.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- antagonistes et inhibiteurs : Complément C5.
- effets indésirables : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- immunologie : Hémoglobinurie paroxystique, Hémolyse.
- sang : Anticorps neutralisants, Hémoglobinurie paroxystique.
- traitement médicamenteux : Hémoglobinurie paroxystique.
- usage thérapeutique : Anticorps monoclonaux humanisés, Inhibiteurs du complément.
- Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Hémolyse, Mâle, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Antibodies, Neutralizing (blood), Complement C5 (antagonists & inhibitors), Complement Inactivating Agents (administration & dosage), Complement Inactivating Agents (adverse effects), Complement Inactivating Agents (therapeutic use), Dose-Response Relationship, Drug, Female, Hemoglobinuria, Paroxysmal (blood), Hemoglobinuria, Paroxysmal (drug therapy), Hemoglobinuria, Paroxysmal (immunology), Hemolysis (drug effects), Hemolysis (immunology), Humans, Male, Middle Aged, Time Factors.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- chemical , antagonists & inhibitors : Complement C5.
- chemical , blood : Antibodies, Neutralizing.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Complement Inactivating Agents.
- blood : Hemoglobinuria, Paroxysmal.
- drug effects : Hemolysis.
- drug therapy : Hemoglobinuria, Paroxysmal.
- immunology : Hemoglobinuria, Paroxysmal, Hemolysis.
- Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Time Factors.
DOI: 10.1002/ajh.24280
PubMed: 26690023
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002150
- to stream PubMed, to step Curation: 002124
- to stream PubMed, to step Checkpoint: 002124
Links to Exploration step
pubmed:26690023Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.</title><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Section of Experimental Haematology, St James's University Hospital, Leeds, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Section of Experimental Haematology, St James's University Hospital, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="Muus, Petra" sort="Muus, Petra" uniqKey="Muus P" first="Petra" last="Muus">Petra Muus</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Szer, Jeffrey" sort="Szer, Jeffrey" uniqKey="Szer J" first="Jeffrey" last="Szer">Jeffrey Szer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hill, Anita" sort="Hill, Anita" uniqKey="Hill A" first="Anita" last="Hill">Anita Hill</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="Hochsmann, Britta" sort="Hochsmann, Britta" uniqKey="Hochsmann B" first="Britta" last="Höchsmann">Britta Höchsmann</name><affiliation wicri:level="4"><nlm:affiliation>Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Kulasekararaj, Austin" sort="Kulasekararaj, Austin" uniqKey="Kulasekararaj A" first="Austin" last="Kulasekararaj">Austin Kulasekararaj</name><affiliation wicri:level="3"><nlm:affiliation>King's College Hospital, Hill, Denmark, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, Hill, Denmark, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Risitano, Antonio M" sort="Risitano, Antonio M" uniqKey="Risitano A" first="Antonio M" last="Risitano">Antonio M. Risitano</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli</wicri:regionArea><wicri:noRegion>Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Liljeholm, Maria" sort="Liljeholm, Maria" uniqKey="Liljeholm M" first="Maria" last="Liljeholm">Maria Liljeholm</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, University Hospital of Umea, Umea, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Hematology Department, University Hospital of Umea, Umea</wicri:regionArea><wicri:noRegion>Umea</wicri:noRegion></affiliation></author><author><name sortKey="Ebrahim, Kurt S" sort="Ebrahim, Kurt S" uniqKey="Ebrahim K" first="Kurt S" last="Ebrahim">Kurt S. Ebrahim</name><affiliation wicri:level="2"><nlm:affiliation>New England Cancer Specialists, Scarborough, Maine.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maine (État)</region></placeName><wicri:cityArea>New England Cancer Specialists, Scarborough</wicri:cityArea></affiliation></author><author><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Ames, Donna" sort="Ames, Donna" uniqKey="Ames D" first="Donna" last="Ames">Donna Ames</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Socie, Gerard" sort="Socie, Gerard" uniqKey="Socie G" first="Gérard" last="Socié">Gérard Socié</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP Hematology Hospital Saint Louis, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP Hematology Hospital Saint Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26690023</idno><idno type="pmid">26690023</idno><idno type="doi">10.1002/ajh.24280</idno><idno type="wicri:Area/PubMed/Corpus">002150</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002150</idno><idno type="wicri:Area/PubMed/Curation">002124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002124</idno><idno type="wicri:Area/PubMed/Checkpoint">002124</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002124</idno><idno type="wicri:Area/Ncbi/Merge">002E97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.</title><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Section of Experimental Haematology, St James's University Hospital, Leeds, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Section of Experimental Haematology, St James's University Hospital, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="Muus, Petra" sort="Muus, Petra" uniqKey="Muus P" first="Petra" last="Muus">Petra Muus</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Hematology, Radboud University Medical Centre, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Szer, Jeffrey" sort="Szer, Jeffrey" uniqKey="Szer J" first="Jeffrey" last="Szer">Jeffrey Szer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hill, Anita" sort="Hill, Anita" uniqKey="Hill A" first="Anita" last="Hill">Anita Hill</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="Hochsmann, Britta" sort="Hochsmann, Britta" uniqKey="Hochsmann B" first="Britta" last="Höchsmann">Britta Höchsmann</name><affiliation wicri:level="4"><nlm:affiliation>Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement><settlement type="city">Ulm</settlement></placeName><orgName type="university">Université d'Ulm</orgName></affiliation></author><author><name sortKey="Kulasekararaj, Austin" sort="Kulasekararaj, Austin" uniqKey="Kulasekararaj A" first="Austin" last="Kulasekararaj">Austin Kulasekararaj</name><affiliation wicri:level="3"><nlm:affiliation>King's College Hospital, Hill, Denmark, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College Hospital, Hill, Denmark, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Risitano, Antonio M" sort="Risitano, Antonio M" uniqKey="Risitano A" first="Antonio M" last="Risitano">Antonio M. Risitano</name><affiliation wicri:level="1"><nlm:affiliation>Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli</wicri:regionArea><wicri:noRegion>Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Liljeholm, Maria" sort="Liljeholm, Maria" uniqKey="Liljeholm M" first="Maria" last="Liljeholm">Maria Liljeholm</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, University Hospital of Umea, Umea, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Hematology Department, University Hospital of Umea, Umea</wicri:regionArea><wicri:noRegion>Umea</wicri:noRegion></affiliation></author><author><name sortKey="Ebrahim, Kurt S" sort="Ebrahim, Kurt S" uniqKey="Ebrahim K" first="Kurt S" last="Ebrahim">Kurt S. Ebrahim</name><affiliation wicri:level="2"><nlm:affiliation>New England Cancer Specialists, Scarborough, Maine.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maine (État)</region></placeName><wicri:cityArea>New England Cancer Specialists, Scarborough</wicri:cityArea></affiliation></author><author><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Ames, Donna" sort="Ames, Donna" uniqKey="Ames D" first="Donna" last="Ames">Donna Ames</name><affiliation wicri:level="2"><nlm:affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Alexion Pharmaceuticals, Inc, Cheshire</wicri:cityArea></affiliation></author><author><name sortKey="Socie, Gerard" sort="Socie, Gerard" uniqKey="Socie G" first="Gérard" last="Socié">Gérard Socié</name><affiliation wicri:level="3"><nlm:affiliation>AP-HP Hematology Hospital Saint Louis, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP Hematology Hospital Saint Louis, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">American journal of hematology</title><idno type="eISSN">1096-8652</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antibodies, Neutralizing (blood)</term><term>Complement C5 (antagonists & inhibitors)</term><term>Complement Inactivating Agents (administration & dosage)</term><term>Complement Inactivating Agents (adverse effects)</term><term>Complement Inactivating Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Hemoglobinuria, Paroxysmal (blood)</term><term>Hemoglobinuria, Paroxysmal (drug therapy)</term><term>Hemoglobinuria, Paroxysmal (immunology)</term><term>Hemolysis (drug effects)</term><term>Hemolysis (immunology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Anticorps neutralisants (sang)</term><term>Complément C5 (antagonistes et inhibiteurs)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hémoglobinurie paroxystique (immunologie)</term><term>Hémoglobinurie paroxystique (sang)</term><term>Hémoglobinurie paroxystique (traitement médicamenteux)</term><term>Hémolyse ()</term><term>Hémolyse (immunologie)</term><term>Inhibiteurs du complément (administration et posologie)</term><term>Inhibiteurs du complément (effets indésirables)</term><term>Inhibiteurs du complément (usage thérapeutique)</term><term>Mâle</term><term>Relation dose-effet des médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Complement C5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Complement Inactivating Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Complément C5</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hemoglobinuria, Paroxysmal</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hemolysis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemoglobinuria, Paroxysmal</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hémoglobinurie paroxystique</term><term>Hémolyse</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hemoglobinuria, Paroxysmal</term><term>Hemolysis</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps neutralisants</term><term>Hémoglobinurie paroxystique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémoglobinurie paroxystique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs du complément</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hémolyse</term><term>Mâle</term><term>Relation dose-effet des médicaments</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26690023</PMID><DateCreated><Year>2016</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2016</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>American journal of hematology</Title><ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation></Journal><ArticleTitle>Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.</ArticleTitle><Pagination><MedlinePgn>E16-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.24280</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hillmen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Experimental Haematology, St James's University Hospital, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muus</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szer</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Höchsmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulasekararaj</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King's College Hospital, Hill, Denmark, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risitano</LastName><ForeName>Antonio M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Neste</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liljeholm</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital of Umea, Umea, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebrahim</LastName><ForeName>Kurt S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>New England Cancer Specialists, Scarborough, Maine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedrosian</LastName><ForeName>Camille L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>Donna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Socié</LastName><ForeName>Gérard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AP-HP Hematology Hospital Saint Louis, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hematol</MedlineTA><NlmUniqueID>7610369</NlmUniqueID><ISSNLinking>0361-8609</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003182">Complement C5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051056">Complement Inactivating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>A3ULP0F556</RegistryNumber><NameOfSubstance UI="C481642">eculizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003182" MajorTopicYN="N">Complement C5</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051056" MajorTopicYN="N">Complement Inactivating Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006457" MajorTopicYN="N">Hemoglobinuria, Paroxysmal</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26690023</ArticleId><ArticleId IdType="doi">10.1002/ajh.24280</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bade-Wurtemberg</li><li>Connecticut</li><li>District de Tübingen</li><li>Grand Londres</li><li>Gueldre</li><li>Maine (État)</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Bruxelles</li><li>Londres</li><li>Melbourne</li><li>Nimègue</li><li>Paris</li><li>Ulm</li></settlement><orgName><li>Université d'Ulm</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name></noRegion><name sortKey="Hill, Anita" sort="Hill, Anita" uniqKey="Hill A" first="Anita" last="Hill">Anita Hill</name><name sortKey="Kulasekararaj, Austin" sort="Kulasekararaj, Austin" uniqKey="Kulasekararaj A" first="Austin" last="Kulasekararaj">Austin Kulasekararaj</name></country><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Muus, Petra" sort="Muus, Petra" uniqKey="Muus P" first="Petra" last="Muus">Petra Muus</name></region></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Szer, Jeffrey" sort="Szer, Jeffrey" uniqKey="Szer J" first="Jeffrey" last="Szer">Jeffrey Szer</name></region></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Hochsmann, Britta" sort="Hochsmann, Britta" uniqKey="Hochsmann B" first="Britta" last="Höchsmann">Britta Höchsmann</name></region></country><country name="Italie"><noRegion><name sortKey="Risitano, Antonio M" sort="Risitano, Antonio M" uniqKey="Risitano A" first="Antonio M" last="Risitano">Antonio M. Risitano</name></noRegion></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name></region></country><country name="Suède"><noRegion><name sortKey="Liljeholm, Maria" sort="Liljeholm, Maria" uniqKey="Liljeholm M" first="Maria" last="Liljeholm">Maria Liljeholm</name></noRegion></country><country name="États-Unis"><region name="Maine (État)"><name sortKey="Ebrahim, Kurt S" sort="Ebrahim, Kurt S" uniqKey="Ebrahim K" first="Kurt S" last="Ebrahim">Kurt S. Ebrahim</name></region><name sortKey="Ames, Donna" sort="Ames, Donna" uniqKey="Ames D" first="Donna" last="Ames">Donna Ames</name><name sortKey="Bedrosian, Camille L" sort="Bedrosian, Camille L" uniqKey="Bedrosian C" first="Camille L" last="Bedrosian">Camille L. Bedrosian</name><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name></country><country name="France"><region name="Île-de-France"><name sortKey="Socie, Gerard" sort="Socie, Gerard" uniqKey="Socie G" first="Gérard" last="Socié">Gérard Socié</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002E97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:26690023
|texte= Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:26690023" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |